These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11049995)

  • 1. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity.
    Seidel C; Børset M; Hjertner O; Cao D; Abildgaard N; Hjorth-Hansen H; Sanderson RD; Waage A; Sundan A
    Blood; 2000 Nov; 96(9):3139-46. PubMed ID: 11049995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma.
    Derksen PW; Keehnen RM; Evers LM; van Oers MH; Spaargaren M; Pals ST
    Blood; 2002 Feb; 99(4):1405-10. PubMed ID: 11830493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.
    Dhodapkar MV; Abe E; Theus A; Lacy M; Langford JK; Barlogie B; Sanderson RD
    Blood; 1998 Apr; 91(8):2679-88. PubMed ID: 9531576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
    Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
    Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins.
    Børset M; Hjertner O; Yaccoby S; Epstein J; Sanderson RD
    Blood; 2000 Oct; 96(7):2528-36. PubMed ID: 11001907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
    Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
    Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen.
    Ridley RC; Xiao H; Hata H; Woodliff J; Epstein J; Sanderson RD
    Blood; 1993 Feb; 81(3):767-74. PubMed ID: 8427968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble syndecan-1 promotes growth of myeloma tumors in vivo.
    Yang Y; Yaccoby S; Liu W; Langford JK; Pumphrey CY; Theus A; Epstein J; Sanderson RD
    Blood; 2002 Jul; 100(2):610-7. PubMed ID: 12091355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease.
    Hjertner O; Torgersen ML; Seidel C; Hjorth-Hansen H; Waage A; Børset M; Sundan A
    Blood; 1999 Dec; 94(11):3883-8. PubMed ID: 10572104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells.
    Holen I; Drury NL; Hargreaves PG; Croucher PI
    Br J Haematol; 2001 Aug; 114(2):414-21. PubMed ID: 11529866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The expression, secretion and regulation of membrane-soluble syndecan-1 in human multiple myeloma cells].
    Li X; Lu Z; Klein B
    Zhonghua Xue Ye Xue Za Zhi; 2000 Nov; 21(11):572-6. PubMed ID: 11225246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: a novel mechanism of tumor-host cross-talk.
    Stewart MD; Ramani VC; Sanderson RD
    J Biol Chem; 2015 Jan; 290(2):941-9. PubMed ID: 25404732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regulation of syndecan expression by osteosarcoma cell lines in response to cytokines but not osteotropic hormones.
    Birch MA; Skerry TM
    Bone; 1999 Jun; 24(6):571-8. PubMed ID: 10375199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloma-derived extracellular vesicles mediate HGF/c-Met signaling in osteoblast-like cells.
    Strømme O; Psonka-Antonczyk KM; Stokke BT; Sundan A; Arum CJ; Brede G
    Exp Cell Res; 2019 Oct; 383(1):111490. PubMed ID: 31283912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
    Aref S; Goda T; El-Sherbiny M
    Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation.
    Subramanian SV; Fitzgerald ML; Bernfield M
    J Biol Chem; 1997 Jun; 272(23):14713-20. PubMed ID: 9169435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
    Yang Y; MacLeod V; Dai Y; Khotskaya-Sample Y; Shriver Z; Venkataraman G; Sasisekharan R; Naggi A; Torri G; Casu B; Vlodavsky I; Suva LJ; Epstein J; Yaccoby S; Shaughnessy JD; Barlogie B; Sanderson RD
    Blood; 2007 Sep; 110(6):2041-8. PubMed ID: 17536013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum syndecan-1: a new independent prognostic marker in multiple myeloma.
    Seidel C; Sundan A; Hjorth M; Turesson I; Dahl IM; Abildgaard N; Waage A; Borset M
    Blood; 2000 Jan; 95(2):388-92. PubMed ID: 10627439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte growth factor and its receptor c-met in multiple myeloma.
    Börset M; Hjorth-Hansen H; Seidel C; Sundan A; Waage A
    Blood; 1996 Nov; 88(10):3998-4004. PubMed ID: 8916966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Syndecan-1 in B lymphoid malignancies.
    Sanderson RD; Børset M
    Ann Hematol; 2002 Mar; 81(3):125-35. PubMed ID: 11904737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.